🇺🇸 FDA
Pipeline program

Enzalutamide

9785-CL-0336

Phase 3 small_molecule active

Quick answer

Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Metastatic Hormone Sensitive Prostate Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials